Risk of Serotonin Syndrome with Quetiapine Monotherapy
The risk of serotonin syndrome from quetiapine (Seroquel) alone without other serotonergic medications is extremely low to negligible in clinical practice. Quetiapine is not classified as a serotonergic agent, and serotonin syndrome requires elevated brain serotonin levels that occur when serotonergic medications are combined 1.
Mechanism and Evidence
Quetiapine functions primarily as a dopamine D2 and serotonin 5-HT2A receptor antagonist—it does not increase serotonin levels through reuptake inhibition, release, or MAO inhibition. The FDA drug label for Seroquel does not list serotonin syndrome as a risk for monotherapy 2.
Serotonin syndrome is triggered when serotonergic medications are combined, not from single-agent use of non-serotonergic drugs 1. The 2020 AACAP guidelines explicitly state that serotonin syndrome occurs when combining two or more serotonergic drugs, listing SSRIs, SNRIs, TCAs, MAOIs, certain opioids (tramadol, meperidine, methadone, fentanyl), stimulants, dextromethorphan, and other agents—but notably not antipsychotics like quetiapine 1.
Important Clinical Caveats
Overdose Situations
The risk profile changes dramatically in overdose scenarios. Case reports document serotonin syndrome following intentional quetiapine overdose (e.g., 350-700 mg ingestions) 3, 4. However, these represent toxic exposures far exceeding therapeutic dosing and often involve co-ingestion of multiple agents.
Drug Interactions to Monitor
While quetiapine monotherapy poses minimal serotonin syndrome risk, be vigilant about:
- Hidden serotonergic agents: Over-the-counter medications (dextromethorphan in cough syrups, St. John's wort), certain pain medications (tramadol, fentanyl), and illicit substances (MDMA, cocaine) 1
- Pharmacodynamic synergism: One case report describes severe toxicity when therapeutic-dose quetiapine was combined with escitalopram, though this involved SIADH and cardiac toxicity rather than classic serotonin syndrome 5
- Antidepressant augmentation: The 2025 INTEGRATE schizophrenia guidelines mention that antidepressant augmentation with antipsychotics requires consideration of "pharmacodynamic (e.g., serotonin syndrome) interactions" 6, reinforcing that risk emerges only with combination therapy
What Actually Causes Concern with Quetiapine Alone
At therapeutic doses, quetiapine's primary risks include:
- Orthostatic hypotension and tachycardia 2
- Metabolic effects (weight gain, diabetes risk)
- QTc prolongation (especially at higher doses)
- Anticholinergic effects 2
- Sedation and cognitive impairment
None of these represent serotonin syndrome.
Clinical Bottom Line
You can confidently prescribe quetiapine as monotherapy without concern for serotonin syndrome. The syndrome requires serotonergic drug combinations—typically involving MAOIs with any serotonergic agent, or multiple non-MAOI serotonergic drugs together 1, 7.
However, always conduct a thorough medication reconciliation before starting quetiapine to identify hidden serotonergic agents (prescription, over-the-counter, herbal, and illicit substances). If combining quetiapine with any serotonergic medication, then standard serotonin syndrome precautions apply: start low, titrate slowly, and monitor for the classic triad of mental status changes, autonomic hyperactivity (hypertension, tachycardia, hyperthermia), and neuromuscular abnormalities (tremor, clonus, hyperreflexia, rigidity) within 24-48 hours of dose changes 7.